The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings. Boat packed with migrants intercepted ...
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
GlobalData on MSN1d
FDA grants 510(k) clearance to Roche’s Tina-quant molarity assayClinicians and laboratory professionals can rely on molar unit measurements to know the Lp(a) particle numbers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback